Compass Therapeutics (CMPX) Cash & Current Investments: 2023-2025
Historic Cash & Current Investments for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to $220.5 million.
- Compass Therapeutics' Cash & Current Investments rose 62.14% to $220.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $562.5 million, marking a year-over-year decrease of 7.90%. This contributed to the annual value of $127.3 million for FY2024, which is 16.51% down from last year.
- According to the latest figures from Q3 2025, Compass Therapeutics' Cash & Current Investments is $220.5 million, which was up 117.17% from $101.5 million recorded in Q2 2025.
- Over the past 5 years, Compass Therapeutics' Cash & Current Investments peaked at $220.5 million during Q3 2025, and registered a low of $101.5 million during Q2 2025.
- In the last 3 years, Compass Therapeutics' Cash & Current Investments had a median value of $152.5 million in 2023 and averaged $152.8 million.
- The largest annual percentage gain for Compass Therapeutics' Cash & Current Investments in the last 5 years was 62.14% (2025), contrasted with its biggest fall of 35.70% (2025).
- Quarterly analysis of 3 years shows Compass Therapeutics' Cash & Current Investments stood at $152.5 million in 2023, then fell by 16.51% to $127.3 million in 2024, then surged by 62.14% to $220.5 million in 2025.
- Its Cash & Current Investments stands at $220.5 million for Q3 2025, versus $101.5 million for Q2 2025 and $113.2 million for Q1 2025.